SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, today announced late-breaking clinical data from ...

Hepatocellular carcinoma (HCC) is a common malignant tumor and the third leading cause of cancer-related mortality. The lack ...

Sandoz has exclusive commercial rights for a biosimilar of ipilimumab in Australia, Canada, Europe, Japan and the United ...

Background: Hepatoblastoma (HBL) and hepatocellular carcinoma (HCC) are respectively the first and the second most common pediatric malignant liver tumors. The purpose of this study was to ...

MEDIA RELEASE Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for treatment of variety of cancer types, targeting net reference medicine sales of USD 2.5 billion[1]Henlius to ...

Research showed that nearly two-thirds of patients sustained clinically meaningful relief over 4 years after a 60-day PNS treatment for chronic low back pain.

Replimune Group, Inc.'s RP1 + OPDIVO for advanced melanoma gains FDA Priority Review. PDUFA date: July 22, 2025. Read more on ...

The downregulation of ADH4 expression induces hepatocyte apoptosis, thereby contributing to liver fibrosis and the initiation of hepatocellular carcinoma ... target malignant cells while ...

The Trade-Adverse Trade Adviser: Once sidelined, President Trump’s counselor Peter Navarro has returned to Washington and ...

These findings align with the proposed mechanism of action for the therapy that involves targeting malignant cells ... first-line HCC patients.” Hepatocellular carcinoma is a rapidly progressing ...